Pharmaceuticals News and Research

RSS

All patients in study clear parasite that causes African sleeping sickness

Immtech International has announced that all 30 patients participating in the concluded Phase IIb extended dose regimen arm of its clinical trial of DB289 for treating African sleeping sickness cleared the parasite that causes African sleeping sickness within the treatment period, with no significant adverse results reported.

11 Nov 2004

Shp2 protein plays a critical role in obesity

A team of researchers led by The Burnham Institute's Gen-Sheng Feng, Ph.D. has discovered that a protein called Shp2 plays a critical role in obesity.

11 Nov 2004

Dementia patients receiving long-term treatment with Reminyl may be able to stay at home for longer compared

Shire Pharmaceuticals Group has announced that Dementia patients receiving long-term treatment with Reminyl (more than 36 months) may be able to stay at home for longer compared to those receiving treatment for shorter periods of time.

10 Nov 2004

Obesity statistics are as bogus as weight-loss scams

The weight-loss industry is finding itself in the crosshairs of the Federal Trade Commission's "Operation Big Fat Lies" -- a crackdown on slimming down pills, powders and patches that are too good to be true. The Center for Consumer Freedom (CCF) recommends that grossly exaggerated statistics and hype from pharmaceutical and weight-loss companies about the nation's so-called "obesity epidemic" also be placed under the federal microscope.

10 Nov 2004

Merck licenses new and improved methods for developing antibiotics from San Diego State University

Two new and improved methods of developing antibiotics discovered at San Diego State University have been licensed to Merck Pharmaceuticals for $300,000, the largest technology transfer agreement so far for SDSU.

9 Nov 2004

Morton Grove Pharmaceuticals increases production of antiviral flu drug, Amantadine

During the current flu vaccine shortage, the Centers for Disease Control and Prevention, Department of Health and Human Services, has issued guidance recommending the use of certain alternative antiviral medications.

8 Nov 2004

Drug reaction breakthrough

The ‘data mining’ research maximises the information extracted from existing drug safety data by cross-referencing much of the existing information on adverse drug reactions.

8 Nov 2004

Vioxx linked with risk of cardiovascular disease

With the support of the National Research Programme (Musculoskeletal Health - Chronic Pain) , researchers at the University of Berne analysed the data in publicly available studies on the anti-inflammatory drug Vioxx.

5 Nov 2004

Vaccine contributions to health highlighted at PAHO meeting

Vaccine programs in the Americas have made major contributions to improving health in the Americas and new vaccines could go even further, said Dr. D.A. Henderson, a global expert who chairs a Pan American Health Organization (PAHO) technical group here today.

4 Nov 2004

Crystal structure of protein AIRs kinase uncovered

Cornell University researchers, who are trying to understand how proteins evolve and function by looking at their structural features, have uncovered the crystal structure of a protein involved in making the building blocks of DNA correctly.

4 Nov 2004

Cyclooxygenase (COX) inhibitors tested in both prevention and treatment clinical trials

Numerous compounds are examined by the National Cancer Institute (NCI) for their potential to prevent or treat cancer. One class of compounds, cyclooxygenase (COX) inhibitors, is currently being tested in both prevention and treatment clinical trials.

4 Nov 2004

Psoriasis trial enters final stage

Solbec Pharmaceuticals Ltd today announced the successful completion of the first two stages of the Phase I clinical trial of its lead compound, CoramsineTM (SBP002), for the treatment of psoriasis.

4 Nov 2004

Generic drugs are still a good buy

A new AARP study found that manufacturers' prices for some generic drugs experienced a rapid rise over the past three years. However, these increases would have added only a few dollars per year to consumers' costs for any one of these products.

4 Nov 2004

Patent litigation the most commonly used generic defense strategy among pharmaceutical companies

Patent litigation remains the most commonly used generic defense strategy among pharmaceutical companies. 71% of drug companies have used legal battles to defend their patents in the past three years, according to research from pharmaceutical business intelligence firm Cutting Edge Information.

4 Nov 2004

Wyeth shows new Phase III data about its investigational antibiotic, tigecycline

Wyeth Pharmaceuticals recently presented exciting new Phase III data about its investigational antibiotic, tigecycline, based on a clinical trial in patients with complicated intra-abdominal infections (cIAI).

4 Nov 2004

Maxim Pharmaceuticals to withdraw NDA for advanced malignant melanoma

Maxim Pharmaceuticals has announced that based upon the negative outcome of it's confirmatory Phase 3 clinical trial (M0104) studying Ceplene(TM) (histamine dihydrochloride) in combination with Interleukin-2 (IL-2) in advanced malignant melanoma patients with liver metastases, it plans to close the treatment protocol approved by the FDA earlier this year.

2 Nov 2004

High-dose statin therapy for aggressive cholesterol-lowering outperforms typical care

Patients treated with high doses of atorvastatin had about a one percent lower annual rate of heart attacks than similar patients receiving usual care, according to a new study in the Nov. 2, 2004 issue of the Journal of the American College of Cardiology.

2 Nov 2004

Researchers find that berries inhibit growth of harmful intestinal bacteria

A research project carried out by VTT Biotechnology and the University of Helsinki has found that cloudberries and raspberries contain a phenol, ellagic tannin, that inhibits the growth of intestinal bacteria.

2 Nov 2004

Possible treatment for the fatal lung disease idiopathic pulmonary fibrosis

They found that the anti-cancer drug imatinib mesylate — commercially known as Gleevec and produced by Novartis Pharmaceuticals — can target a gene critical to controlling the disease process. Previously, there had been no treatment and patients usually did not survive beyond three years of diagnosis. Now the treatment is undergoing clinical trials at Mayo Clinic.

2 Nov 2004

Study results suggest that metronidazole and clindamycin differ in their effects on microbes in women with bacterial vaginosis

In the first study to directly compare the emergence of antibiotic resistance following topical treatment between two antibiotics routinely prescribed for a common vaginal infection, researchers from the Magee-Womens Research Institute have found antibiotic-resistant bacteria more likely to develop with the drug clindamycin than metronidazole.

1 Nov 2004

Pharmaceuticals News and Research

All patients in study clear parasite that causes African sleeping sickness

Shp2 protein plays a critical role in obesity

Dementia patients receiving long-term treatment with Reminyl may be able to stay at home for longer compared

Obesity statistics are as bogus as weight-loss scams

Merck licenses new and improved methods for developing antibiotics from San Diego State University

Morton Grove Pharmaceuticals increases production of antiviral flu drug, Amantadine

Drug reaction breakthrough

Vioxx linked with risk of cardiovascular disease

Vaccine contributions to health highlighted at PAHO meeting

Crystal structure of protein AIRs kinase uncovered

Cyclooxygenase (COX) inhibitors tested in both prevention and treatment clinical trials

Psoriasis trial enters final stage

Generic drugs are still a good buy

Patent litigation the most commonly used generic defense strategy among pharmaceutical companies

Wyeth shows new Phase III data about its investigational antibiotic, tigecycline

Maxim Pharmaceuticals to withdraw NDA for advanced malignant melanoma

High-dose statin therapy for aggressive cholesterol-lowering outperforms typical care

Researchers find that berries inhibit growth of harmful intestinal bacteria

Possible treatment for the fatal lung disease idiopathic pulmonary fibrosis

Study results suggest that metronidazole and clindamycin differ in their effects on microbes in women with bacterial vaginosis

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News